RAPID MICRO BIOSYSTEMS, INC.

Listed Company

RPIDCIK 0001380106NasdaqEmerging GrowthLaboratory Analytical InstrumentsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$33.59M

Net Income

$-47.12M

Total Assets

$74.85M

Equity

$33.21M

Shares Out

—

Op. Cash Flow

$-31.06M

Business

Rapid Micro Biosystems, Inc. is an innovative life sciences technology company that automates microbial quality control in pharmaceutical manufacturing. It offers the Growth Direct platform—a fully automated MQC system—along with proprietary consumable plates, LIMS connection software, and comprehensive validation, installation, maintenance and customer support services. Its business is organized around system sales, recurring consumables and service/validation contracts, software integration and development of new applications such as rapid sterility. The company sells globally via direct sales, distributors and a co‑exclusive distribution agreement with MilliporeSigma into pharmaceutical, medical device and related industrial QC markets.

Summary from filing dated 2025-02-28

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	34	28	23	17	23
Research and development	14	15	13	13	10
Sales and marketing	12	13	13	15	12
General and administrative	23	22	25	27	18
Total costs and operating expenses	81	78	79	80	70
Loss from operations	−47	−50	−57	−63	−47
Interest income	2	3	—	—	—
Interest expense	−1	−40,000	—	—	—
Other expense, net	−110,000	−112,000	−83,000	59,000	−850,000
Total other income, net	309,000	3	4	2	−26
Loss before income taxes	−47	−47	−52	−61	−73
Income tax expense	40,000	22,000	31,000	−576,000	91,000
Net loss	−47	−47	−52	−61	−74
Net loss per share basic (in dollars per share)	−1.05	−1.08	−1.22	−1.43	−3.94
Net loss per share diluted (in dollars per share)	−1.05	−1.08	−1.22	−1.43	−3.94
Weighted average common shares outstanding - basic (in shares)	45	44	43	42	20
Weighted average common shares outstanding - diluted (in shares)	45	44	43	42	20

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	20	17	24	27	178
Short-term investments	18	34	68	82	15
Accounts receivable	3	8	6	5	5
Inventory, net	18	20	20	21	16
Prepaid expenses and other current assets	2	2	3	3	4
Total current assets	61	81	120	139	218
Property and equipment, net	9	11	13	14	11
Right-of-use assets	4	5	6	7	—
Other long-term assets	319,000	531,000	770,000	1	1
Restricted cash	300,000	400,000	300,000	300,000	300,000
Total assets	75	98	143	191	241
Accounts payable	4	3	2	5	4
Accrued expenses and other current liabilities	8	7	10	8	11
Deferred revenue	5	7	6	5	3
Lease liabilities, short-term	1	1	1	766,000	—
Total current liabilities	18	18	19	19	18
Notes payable, net	19	0	—	—	—
Warrant liability	186,000	0	—	—	—
Lease liabilities, long-term	4	5	6	7	—
Other long-term liabilities	397,000	298,000	263,000	229,000	1
Total liabilities	42	23	25	26	20
Commitments and contingencies (Note 14)	—	—	—	—	—
Preferred stock	0	0	0	0	0
Additional paid-in capital	555	550	546	541	536
Accumulated deficit	−522	−475	−428	−376	−315
Accumulated other comprehensive income	11,000	39,000	−101,000	−1	−16,000
Total stockholders equity	33	75	118	164	221
Total liabilities and stockholders equity	75	98	143	191	241

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization expense	3	3	3	3	2
Noncash interest expense	97,000	0	—	—	—
Stock-based compensation expense	4	4	5	4	2
Provision for excess & obsolete inventory	1	95,000	34,000	326,000	60,000
Noncash lease expense	1	1	—	—	—
Gain on revaluation of warrant liability	−131,000	0	—	—	20
Accretion on investments	351,000	−1	−2	−662,000	−3,000
Other	34,000	34,000	34,000	−107,000	14,000
Accounts receivable	4	−2	−163,000	−364,000	−17,000
Inventory	1	−335,000	1	−6	−7
Prepaid expenses and other current assets	320,000	403,000	272,000	578,000	−1
Other long-term assets	64,000	−150,000	5,000	179,000	−851,000
Accounts payable	2	562,000	−3	1	−524,000
Accrued expenses and other current liabilities	28,000	−4	1	−3	2
Other long-term liabilities	64,000	0	—	0	−30,000
Deferred revenue	−2	626,000	1	1	−1
Net cash used in operating activities	−31	−44	−45	−59	−55
Purchases of property and equipment	−850,000	−1	−2	−7	−3
Purchases of investments	−27	−35	−62	−179	−25
Sales of investments	3	4	0	—	—
Maturity of investments	40	69	106	93	15
Net cash provided by investing activities	14	37	42	−93	−13
Proceeds from issuance of Class A common stock - stock option exercise	491,000	7,000	6,000	566,000	403,000
Proceeds from issuance of Class A common stock - employee stock purchase plan	162,000	231,000	180,000	160,000	0
Proceeds from issuance of debt	20	0	—	—	—
Payments of debt issuance costs	−878,000	0	—	—	—
Issuance of Class A common stock under the ATM offering	445,000	0	—	—	—
Tax withholding on settlement of restricted stock units	−419,000	0	—	—	—
Payments on finance lease obligations	−30,000	−35,000	−37,000	−33,000	—
Net cash provided by financing activities	20	203,000	149,000	693,000	217
Net increase (decrease) in cash, cash equivalents and restricted cash	3	−7	−3	−151	148
Cash paid for interest	770,000	40,000	38,000	42,000	3
Purchases of property and equipment in accounts payable/accrued expenses	12,000	309,000	443,000	561,000	2
Recognition of warrant liability in connection with debt issuance	317,000	0	—	—	—
Warrant to purchase Class A common stock	317,000	0	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro